Press Release

MS Pharma Selects IQVIA's OCE Solution

Mar 29, 2021

[March 11, 2021] IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that MS Pharma has signed an agreement with IQVIA to deploy a selection of applications from its Orchestrated Customer Engagement (OCE) platform, including OCE Remote and OCE Optimizer, in addition to OneKey HCP/HCO reference data services. These solutions will be deployed in several countries in the Middle East, Africa, and Mediterranean regions, starting with Algeria and Greece. MS Pharma is a leading regional pharmaceutical company in the MENA region (the Middle East and North Africa), headquartered in Amman, Jordan and with new management offices in Zug, Switzerland.

“As MS Pharma, our mission is to improve our communities’ quality of life by increasing the access to high quality and affordable products,” said Burak Ozden, Corporate Head of Digital Commercial Operations. “MS Pharma is undergoing a digital transformation journey. Digitalization is an important topic for all pharma companies and COVID-19 has increased the need for digital tools to communicate to customers from different channels. We’re looking for further integration of IQVIA systems to OCE.”

IQVIA’s OCE platform is a suite of applications that breaks down internal barriers by seamlessly connecting sales, account management, marketing, and other functions to enhance the customer experience, strengthen relationships and drive performance. OCE is a SaaS-based platform built on best-in-class technologies such as Salesforce, Mulesoft, Heroku and others. With unique capabilities, such as predictive analytics and machine learning, OCE provides an intuitive user experience, AI-enabled recommendations, fluid integration with other applications to deliver smarter, coordinated engagements with healthcare professionals.

“We are excited to have MS Pharma on our Orchestrated Customer Engagement Platform,” said Yasmine Arim, General Manager of IQVIA Algeria. “This orchestrated model will enable our client to improve their customers' experiences, build trust, and optimize resource allocation across all engagement activities, especially within the complex context related to COVID-19.”

MS Pharma joins 140 other life sciences customers that have selected IQVIA OCE’s innovative solutions to advance customer engagement.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 70,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

About MS Pharma

MS Pharma is a leading regional pharmaceutical company in the MENA region (the Middle East and North Africa), well-positioned for fast business growth. Headquartered in Amman, Jordan, and with new management offices in Zug, Switzerland, MS Pharma markets a wide range of generic and biotech products and is active in several therapeutic areas, including cardiovascular, CNS (central nervous system), respiratory, and oncology. With R&D and manufacturing facilities in Greece, Algeria, Jordan and Saudi Arabia, the company manufactures several dosage forms including solids, liquids, cytotoxic drugs, and sterile injectables. Through its subsidiary, Genepharm, Greece, the company also out-licenses quality generic pharmaceuticals to a wide customer base in Europe. MS Pharma employs over 2700 people in 13 countries and has a turnover of USD 240 million (2019).

Contact Us